# US 2019/0375821 A1 · Cancer treatment composition for inhibiting tumor angiogenesis, containing vegf deep blocker, and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375821 A1
- Document ID: US20190375821A1
- Status: Published application
- Kind: A1
- Application number: 16/311,822
- Filed: 2016-07-05
- Published: 2019-12-12
- Earliest claimed: 2016-07-05
- Assignees: Ibentrus, Inc.
- Applicants: IBENTRUS, Inc.
- Inventors: Hoeon KIM; Hyun-ju LEE
- Web page: https://patentgrep.com/patent/US20190375821A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/71: for growth factors; for growth regulators
- A61P 35/00: Antineoplastic agents
- C07K 14/4702: {Regulators; Modulating activity}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The present invention relates to a cancer treatment composition for inhibiting angiogenesis, and a preparation method therefor. An angiogenesis inhibitor according to the present invention is a cancer treatment composition comprising a fusion protein comprising a vascular endothelial growth factor-binding domain of vascular endothelial growth factor receptor 1 (VEGFR1) and a b1 domain of neuropilin-1 (NRP1). The novel fusion protein is an angiogenesis inhibitor for blocking the binding of VEGF to a receptor in the cell membrane, and has an effect of inhibiting the proliferation of cancer cells and the growth and metastasis of cancer. In addition, the fusion protein can be used as an anti-cancer agent and exhibits an effective anti-cancer effect at a lower dose than that of a conventional angiogenesis inhibitor.

## Claims

### Claim 1

A fusion protein comprising an Ig2 domain of vascular endothelial growth factor receptor 1 (VEGFR1) and a b1 domain of neuropilin 1 (NRP1).

### Claim 2 (depends on 1)

The fusion protein of claim 1, which comprises amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.

### Claim 3 (depends on 2)

The fusion protein of claim 2, which further comprises an amino acid sequence of SEQ ID NO: 4.

### Claim 4 (depends on 3)

The fusion protein of claim 3, which comprises an amino acid sequence of SEQ ID NO: 5.

### Claim 5 (depends on 1)

A composition for cancer treatment, comprising the fusion protein of any one of claim 1.

### Claim 6 (depends on 1)

A DNA fragment encoding the fusion protein of claim 1.

### Claim 7 (depends on 6)

A recombinant vector comprising the DNA fragment of claim 6.

### Claim 8 (depends on 7)

A transformed cell obtained by transforming a host cell with the recombinant vector of claim 7.

### Claim 9 (depends on 8)

The cell of claim 8, wherein the host cell is HEK293E.

### Claim 10 (depends on 8)

A method of preparing a protein for cancer treatment, comprising
(a) culturing the transformed cell of claim 8 to produce a fusion protein; and
(b) separating the fusion protein from the culture solution of said cells.

### Claim 11 (depends on 1)

A method of treating cancer, comprising administering the fusion protein of claim 1 to a patient in need of treating cancer.

### Claim 12 (depends on 11)

The method of claim 11, wherein the fusion protein comprises amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3.

### Claim 13 (depends on 11)

The method of claim 11, wherein the fusion protein further comprises an amino acid sequence of SEQ ID NO: 4.

### Claim 14 (depends on 11)

The method of claim 11, wherein the fusion protein comprises an amino acid sequence of SEQ ID NO: 5.

### Claim 15 (depends on 1)

The fusion protein of claim 1, which further comprises an amino acid sequence of SEQ ID NO: 4.
